{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T04:05:46Z","timestamp":1746849946353,"version":"3.40.5"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Objective: To retrospectively analyze outcomes of patients who received definitive pelvic irradiation for clinically pelvic node-positive (cT1-4N1M0) prostate cancer (PCa).<\/jats:p>\n               <jats:p>Materials and methods: Clinical records of 148 patients with cT1-4N1M0 PCa treated with definitive pelvic radiotherapy (RT) between 2011 and 2015 were retrospectively collected from 25 institutions by the Japanese Radiation Oncology Study Group. The median age, initial prostate-specific antigen (PSA) level, and biologically effective dose (BED) to the prostate with \u03b1\/\u03b2 of 1.5\u00a0Gy were 69 (interquartile range [IQR], 65\u201374.3) years, 41.5 (IQR, 20.3\u201389) ng\/ml, and 177.3 (IQR, 163.3\u2013182) Gy, respectively. All patients underwent neoadjuvant androgen-deprivation therapy (ADT) for a median duration of 10\u00a0months. Most patients (141; 95.2%) received concurrent ADT during the irradiation period. The median duration of adjuvant ADT was 16 (IQR, 5\u201327.8) months. The Phoenix definition was used to assess biochemical failure.<\/jats:p>\n               <jats:p>Results: The median follow-up period was 53.5\u00a0months (IQR, 41\u201369.3). The 5-year overall survival (OS) probability was 86.8%. The 5-year biochemical failure-free survival and clinical progression-free survival rates were 69.6% and 76.3%, respectively. Multivariate analysis indicated the BED to the prostate to be a significant prognostic factor for OS. Regarding late adverse events, the estimated cumulative incidences of late Grade 2 or higher gastrointestinal and genitourinary toxicities at 5\u00a0years were 8.2% and 5.8%, respectively.<\/jats:p>\n               <jats:p>Conclusion: Long-term ADT combined with definitive pelvic external beam RT for cT1-4N1M0 PCa leaded to favorable outcomes. Future prospective studies should validate the suggested survival benefit of local dose escalation to the prostate in this cohort.<\/jats:p>","DOI":"10.1093\/jrr\/rraf005","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T10:12:07Z","timestamp":1741342327000},"page":"157-166","source":"Crossref","is-referenced-by-count":0,"title":["Prostate dose escalation may positively impact survival in patients with clinically node-positive prostate cancer definitively treated by radiotherapy: surveillance study of the Japanese Radiation Oncology Study Group (JROSG)"],"prefix":"10.1093","volume":"66","author":[{"given":"Toshiya","family":"Maebayashi","sequence":"first","affiliation":[{"name":"Department of Radiology, Nihon University School of Medicine , 30-1, Ooyaguchi Kami-cho, Itabashi-ku, Tokyo 173-8610 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Mizowaki","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine , Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Hospital of the National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Sciences and Technology , 4-9-7 Anagawa, Inage, Chiba 263-8555 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyonao","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine , Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Inaba","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Asakura","sequence":"additional","affiliation":[{"name":"Radiation and Proton Therapy Center, Shizuoka Cancer Center Hospital , 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromitsu","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City University West Medical Center , 1-1-1 Hirate-cho, Kita-ku, Nagoya 462-8508 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Itasaka","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Kurashiki Central Hospital , 1-1-1 Miwa, Kurashiki, Okayama 710-8602 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Wada","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Jikei University School of Medicine , 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo 105-8471 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakuni","family":"Sakaguchi","sequence":"additional","affiliation":[{"name":"Department of Radiology, Nihon University School of Medicine , 30-1, Ooyaguchi Kami-cho, Itabashi-ku, Tokyo 173-8610 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Jingu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tohoku University Graduate School of Medicine , 1-1 Seiryo-chou, Aoba-ku, Sendai 980-8574 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Akiba","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tokai University School of Medicine , 143 Shimokasuya, Isehara, Kanagawa 259-1193 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuo","family":"Tomita","sequence":"additional","affiliation":[{"name":"Department of Radiology, Nagoya City University Graduate School of Medical Sciences , 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsumasa","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Hamamatsu University School of Medicine , 1-20-1 Handayama, Chuo-ku, Hamamatsu city, Shizuoka 431-3192,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Japanese Radiation Oncology Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"key":"2025050905363264200_ref1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2025050905363264200_ref2","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.ijrobp.2014.01.008","article-title":"The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study","volume":"88","author":"Rusthoven","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025050905363264200_ref3","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.eururo.2013.09.025","article-title":"Predicting survival of patients with node-positive prostate cancer following multimodal treatment","volume":"65","author":"Abdollah","year":"2014","journal-title":"Eur Urol"},{"key":"2025050905363264200_ref4","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.eururo.2014.07.020","article-title":"Impact of the site of lymph node metastases on survival in patients with node-positive prostate cancer","volume":"68","author":"Gandaglia","year":"2015","journal-title":"Eur Urol"},{"key":"2025050905363264200_ref5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer\u20142020 update. Part II: treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"volume-title":"NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer","key":"2025050905363264200_ref6"},{"key":"2025050905363264200_ref7","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiotherapy in high-risk and node-positive prostate cancer (POP-RT): outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025050905363264200_ref8","doi-asserted-by":"publisher","first-page":"7859","DOI":"10.1002\/cam4.5554","article-title":"Ten-year outcomes of whole-pelvic intensity-modulated radiation therapy for prostate cancer with regional lymph node metastasis","volume":"12","author":"Nakamura","year":"2023","journal-title":"Cancer Med"},{"key":"2025050905363264200_ref9","doi-asserted-by":"publisher","first-page":"289.e19","DOI":"10.1016\/j.urolonc.2018.09.016","article-title":"Local failure is a dominant mode of recurrence in locally advanced and clinical node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy","volume":"37","author":"Hayman","year":"2019","journal-title":"Urol Oncol"},{"key":"2025050905363264200_ref10","doi-asserted-by":"publisher","first-page":"6629","DOI":"10.1002\/cam4.2985","article-title":"Clinical outcomes of definitive whole pelvic radiotherapy for clinical lymph node metastatic prostate cancer","volume":"9","author":"Tsuchida","year":"2020","journal-title":"Cancer Med"},{"key":"2025050905363264200_ref11","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.3390\/cancers13153868","article-title":"Intensity-modulated radiation therapy with simultaneous integrated boost for clinically node-positive prostate cancer: a single-institutional retrospective study","volume":"13","author":"Onishi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025050905363264200_ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109746","article-title":"Impact of prostate radiotherapy on survival outcomes in clinically node-positive prostate cancer: a multicentre retrospective analysis","volume":"186","author":"Elumalai","year":"2023","journal-title":"Radiother Oncol"},{"key":"2025050905363264200_ref13","doi-asserted-by":"publisher","first-page":"931.e1","DOI":"10.1016\/j.urolonc.2020.08.018","article-title":"The prognosis and the impact of radiotherapy in clinically regional lymph node-positive prostate cancer: which patients are candidates for local therapy with radiation?","volume":"38","author":"Ieiri","year":"2020","journal-title":"Urol Oncol"},{"key":"2025050905363264200_ref14","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025050905363264200_ref15","first-page":"90","volume-title":"Japanese Clinical Practice Guidelines for Prostate Cancer 2012 Edition","author":"Japanese Urological Association","year":"2012"},{"volume-title":"Common Terminology Criteria for Adverse Events v4.0 (CTCAE)","key":"2025050905363264200_ref16"},{"key":"2025050905363264200_ref17","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/s0360-3016(98)00438-6","article-title":"Fractionation and protraction for radiotherapy of prostate carcinoma","volume":"43","author":"Brenner","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025050905363264200_ref18","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/s0360-3016(03)00132-9","article-title":"What hypofractionated protocols should be tested for prostate cancer?","volume":"56","author":"Fowler","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025050905363264200_ref19","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/j.ijrobp.2010.10.075","article-title":"Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: \u03b1\/\u03b2 = 1.4 (0.9-2.2) Gy","volume":"82","author":"Miralbell","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025050905363264200_ref20","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1001\/jamaoncol.2015.4350","article-title":"Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial","volume":"2","author":"James","year":"2016","journal-title":"JAMA Oncol"},{"key":"2025050905363264200_ref21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.radonc.2019.05.016","article-title":"Radiotherapy for node-positive prostate cancer: 2019 recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group","volume":"140","author":"Lieng","year":"2019","journal-title":"Radiother Oncol"},{"key":"2025050905363264200_ref22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","article-title":"Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis","volume":"76","author":"Burdett","year":"2019","journal-title":"Eur Urol"},{"key":"2025050905363264200_ref23","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1001\/jamaoncol.2015.2316","article-title":"Dose-escalated irradiation and overall survival in men with nonmetastatic prostate cancer","volume":"1","author":"Kalbasi","year":"2015","journal-title":"JAMA Oncol"},{"key":"2025050905363264200_ref24","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.ijrobp.2007.11.066","article-title":"Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes","volume":"71","author":"Zelefsky","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025050905363264200_ref25","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.eururo.2008.05.023","article-title":"Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy","volume":"54","author":"Schumacher","year":"2008","journal-title":"Eur Urol"},{"key":"2025050905363264200_ref26","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.eururo.2008.09.043","article-title":"Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy","volume":"55","author":"Briganti","year":"2009","journal-title":"Eur Urol"},{"key":"2025050905363264200_ref27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.eururo.2013.03.053","article-title":"Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy","volume":"65","author":"Touijer","year":"2014","journal-title":"Eur Urol"},{"key":"2025050905363264200_ref28","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S1470-2045(08)70203-1","article-title":"MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study","volume":"9","author":"Heesakkers","year":"2008","journal-title":"Lancet Oncol"},{"key":"2025050905363264200_ref29","doi-asserted-by":"publisher","first-page":"4470","DOI":"10.3390\/cancers14184470","article-title":"Bone scintigraphy versus PSMA-targeted PET\/CT or PET\/MRI in prostate cancer: lessons learned from recent systematic reviews and meta-analyses","volume":"14","author":"Dondi","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["Journal of Radiation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jrr\/article-pdf\/66\/2\/157\/62309900\/rraf005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jrr\/article-pdf\/66\/2\/157\/62309900\/rraf005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T09:36:41Z","timestamp":1746783401000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jrr\/article\/66\/2\/157\/8058838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,3,7]]},"published-print":{"date-parts":[[2025,3,24]]}},"URL":"https:\/\/doi.org\/10.1093\/jrr\/rraf005","relation":{},"ISSN":["0449-3060","1349-9157"],"issn-type":[{"type":"print","value":"0449-3060"},{"type":"electronic","value":"1349-9157"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,3]]}}}